Plasma MMP-2, MMP-9 and N-BNP in Long-Term Survivors Following Complicated Myocardial Infarction: Relation to Cardiac Magnetic Resonance Imaging Measures of Left Ventricular Structure and Function

Journal of Cardiac Failure

Volumn 13, Issue 10, 2007, Pages 843-849

  Orn, Stein ^a   Manhenke, Cord ^a   Squire, Iain B ^b   Ng, Leong ^b   Anand, Inder ^c   Dickstein, Kenneth ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

cardiac magnetic resonance; gelatinases; Long term remodeling; myocardial infarction; natriuretic peptides; scarring

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GELATINASE A; GELATINASE B;

AGED; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CAPTOPRIL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; LOSARTAN; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 36649006686     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2007.07.006     Document Type: Article

References (43)

1. Weisman H.F., and Healy B. Myocardial scar expansion, scar extension and reinfarction: pathophysiological concepts. Prog Cardiovasc Dis 30 (1987) 73-110
2. Creemers E.E.J.M., Cleutjens J.P.M., Smits J.F.M., and Daemen M.J.A.P. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?. Circ Res 89 (2001) 201-210
3. Mukherjee R., Brinsa T.A., Dowdy K.B., Scott A.A., Baskin J.M., Deschamps A.M., et al. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 107 (2003) 618-625
4. Wilson E.M., Moainie S.L., Baskin J.M., Lowry A.S., Deschamps A.M., Mukherjee R., et al. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation 107 (2003) 2857-2863
5. Squire I.B., Evans J., Ng L.L., Loftus I., and Thompson M.T. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Cardiac Fail 10 (2004) 328-333
6. Kaden J.J., Dempfle C.E., Sueselbeck T., Brueckmann M., Poerner T.C., Haghi D., et al. Time-dependent changes in the plasma concentration of matrix metalloproteinase 9 after acute myocardial infarction. Cardiology 99 (2003) 140-144
7. Renko J., Kalela A., Jaakkola O., Laine S., Hoyhtya M., Alho H., et al. Serum matrix metalloproteinase-9 is elevated in men with a history of myocardial infarction. Scand J Clin Lab Invest 64 (2004) 255-261
8. Kai H., Ikeda H., Yasukawa H., Kai M., Seki Y., Kuwahara F., Ueno T., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32 (1998) 368-372
9. Inokubo Y., Hanada H., Ishizaka H., Fukushi T., Kamada T., and Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 141 (2001) 211-217
10. Richards A.M., Nicholls M.G., Yandle T.G., Frampton C., Espiner E.A., Turner J.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97 (1998) 1921-1929
11. Omland T., Persson A., Ng L., O'Brien R., Karlsson T., Herlitz J., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106 (2002) 2913-2918
12. Heymans S., Luttun A., Nuyens D., Theilmeier G., Creemers E., Moons L., et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5 (1999) 1135-1142
13. Kelly D., Cockerill G., Ng L.L., Thompson M., Khan S., Samani N.J., and Squire I.B. Plasma matrix metalloproteinase-9 and left ventricular remodeling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 28 (2007) 711-718
14. Wu E., Judd R.M., Vargas J.D., Klocke F.J., Bonow R.O., and Kim R.J. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 357 (2001) 21-28
15. Simonetti O.P., Kim R.J., Fieno D.S., Hillenbrand H.B., Wu E., Bundy J.M., et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology 218 (2001) 215-223
16. Bellenger N.G., Davies L.C., Francis J.M., Coats A.J., and Penell D.J. Reduction in samplesize for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2 (2000) 271-278
17. Dickstein K., and Kjekshus J. Comparison of the effects of losartan and captopril on mortality and morbidity in patients following acute myocardial infarction: The OPTIMAAL Trial. Lancet 360 (2002) 752-760
18. Omland T., Persson A., Ng L., O'Brien R., Karlsson T., Herlitz J., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106 (2002) 2913-2918
19. Gerber B.L., Garot J., Bluemke D.A., Wu K.C., and Lima J.A. Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction. Circulation 106 (2002) 1083-1089
20. Tziakas D.N., Chalikias G.K., Parissis J.T., Hatzinikolaou E.I., Papadopoulos E.D., Tripsiannis G.A., et al. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int J Cardiol 94 (2004) 269-277
21. Weber K.T. Extracellular matrix remodeling in heart failure. A role for de novo angiotensin II generation. Circulation 96 (1997) 4065-4082
22. Webb C.S., Bonnema D.D., Ahmed S.H., Leonardi A.H., McClure C.D., Clark L.L., et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 114 (2006) 1020-1027
23. Cleutjens J.P., Kandala J.C., Guarda E., Guntaka R.V., and Weber K.T. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 27 (1995) 1281-1292
24. Tsuruda T., Boerrigter G., Huntley B.K., Noser J.A., Cataliotti A., Costello-Boerrigter L.C., et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 91 (2002) 1127-1134
25. Jugdutt B. Ventricular remodeling after infarction and the extracellular collagen matrix, when is enough enough?. Circulation 108 (2003) 1395-1403
26. Olivetti G., Capasso J.M., Meggs L.G., Sonnenblick E.H., and Anversa P. Cellular basis of chronic ventricular remodeling after myocardial infarction in rats. Circ Res 68 (1991) 856-869
27. Magga J., Marttila M., Mäntymaa P., Vuolteenaho O., and Ruskoaho H. Brain natriuretic peptide in plasma, atria, and ventricles of vasopressin and phenylephrine-infused conscious rats. Endocrinology 134 (1994) 2505-2515
28. Jones C.B., Sane D.C., and Herrington D.M. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 59 (2003) 812-823
29. Spinale F.G., Coker M.L., Heung L.J., Bond B.R., Gunasinghe H.R., Etoh T., et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102 (2000) 1944-1949
30. Li Y.Y., Feng Y., McTiernan C.F., Pei W., Moravec C.S., Wang P., Rosenblum, et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 104 (2001) 1147-1157
31. Ries C., and Petrides P.E. Cytokine regulation of matrix metalloproteinase activity and regulatory dysfunction in disease. Biol Chem 376 (1995) 345-355
32. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 378 (1997) 151-160
33. Sabatine M.S., Morrow D.A., de Lemos J.A., Omland T., Desai M.Y., Tanasijevic M., et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 44 (2004) 1988-1995
34. Ørn S., Manhenke C., Anand I., Squire I., Nagel E., Edvardsen T., et al. Effect of left ventricular scar size, location and transmurality on left ventricular remodeling with healed myocardial infarction. Am J Cardiol 99 (2007) 1109-1114
35. Groenning B.A., Nilsson J.C., Sondergaard L., Kjaer A., Larsson H.B.W., and Hildebrandt P.R. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohormonal plasma concentrations. Eur J Heart Failure 3 (2001) 699-708
36. Nelson C., Case C., McCrohon J., and Marwick T.H. Relationship of extent and nature of dysfunctional myocardium to brain natriuretic peptide in patients with ischemic left ventricular dysfunction. Int J Cardiovasc Imaging 21 (2005) 295-300
37. Nishikawa N., Yamamoto K., Sakata Y., Mano T., Yoshida J., Miwa T., et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res 57 (2003) 766-774
38. Thomas C.V., Coker M.L., Zellner J.L., Handy J.R., Crumbley III A.J., and Spinale F.G. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97 (1998) 1708-1715
39. Reinhardt D., Sigusch H.H., Hensse J., Tyagi S.C., Korfer R., and Figulla H.R. Cardiac remodeling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 88 (2002) 525-530
40. Rouet-Benzineb P., Buhler J.M., Dreyfus P., Delcourt A., Dorent R., Perennec J., et al. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail 1 (1999) 337-352
41. Coker M.L., Zellner J.L., Crumbley A.J., and Spinale F.G. Defects in matrix metalloproteinase inhibitory stoichiometry and selective MMP induction in patients with nonischemic or ischemic dilated cardiomyopathy. Ann N Y Acad Sci 878 (1999) 559-562
42. Ohtsuka T., Hamada M., Saeki H., Ogimoto A., Hara Y., Shigematsu Y., et al. Serum levrls of matrix metalloproteases and tumor necrosis factor-alpha in patients with idiopathic dilated cardiomyopathy and effect of carvedilol on these levels. Am J Cardiol 91 (2003) 1024-1027
43. Wilson E.M., Gunasinghe H.R., Coker M.L., Sprunger P., Lee-Jackson D., Bozkurt B., et al. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 8 (2002) 390-398